ArticlePloS one2025
Prevalence and characteristics of metabolic dysfunction-associated steatohepatitis among pediatric patients in the MarketScan Databases.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere are few epidemiologic studies of the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) among pediatric populations.
objectiveTo estimate the cross-sectional prevalence of MASH in the pediatric (<18 years) populations of MerativeTM MarketScan® Commercial Database (Commercial) and MerativeTM MarketScan® Multi-State Medicaid Database (Medicaid).
methodsPediatric patients with ≥1 medical encounter from 1/1/2020 to 12/31/2020 and ≥6 months of continuous enrollment before the most recent medical encounter were included. MASH was confirmed by an ICD-10-CM diagnosis code for MASH (K75.81) in the medical history since 1/1/2016.
resultsA total of 1,476 and 410 pediatric MASH patients were identified in Medicaid and Commercial databases respectively, with a prevalence of 0.036% (95% confidence interval (CI): 0.034%, 0.038%) in Medicaid, as compared to 0.011% (95% CI: 0.010%, 0.012%) in Commercial. Prevalence of MASH increased by age. MASH was more prevalent in those who were male, obese, had T2D, and had metabolic syndrome. Among all pediatric MASH patients, the majority were ≥10 years old, male, and obese. DISCUSSION: MASH is more prevalent among pediatric patients with comorbid conditions such as metabolic syndrome, obesity, and T2D, which appears to be similar to young adults. Rising prevalence of childhood obesity and related comorbid conditions, and the progressive nature of MASH, make this an area of increasing medical need. Prescreening MASH among high-risk patients with these comorbidities is needed for target intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.